Literature DB >> 34592195

Leveraging external data in the design and analysis of clinical trials in neuro-oncology.

Rifaquat Rahman1, Steffen Ventz2, Jon McDunn3, Bill Louv3, Irmarie Reyes-Rivera4, Mei-Yin C Polley5, Fahar Merchant6, Lauren E Abrey7, Joshua E Allen8, Laura K Aguilar9, Estuardo Aguilar-Cordova9, David Arons10, Kirk Tanner10, Stephen Bagley11, Mustafa Khasraw12, Timothy Cloughesy13, Patrick Y Wen14, Brian M Alexander15, Lorenzo Trippa2.   

Abstract

Integration of external control data, with patient-level information, in clinical trials has the potential to accelerate the development of new treatments in neuro-oncology by contextualising single-arm studies and improving decision making (eg, early stopping decisions). Based on a series of presentations at the 2020 Clinical Trials Think Tank hosted by the Society of Neuro-Oncology, we provide an overview on the use of external control data representative of the standard of care in the design and analysis of clinical trials. High-quality patient-level records, rigorous methods, and validation analyses are necessary to effectively leverage external data. We review study designs, statistical methods, risks, and potential distortions in using external data from completed trials and real-world data, as well as data sources, data sharing models, ongoing work, and applications in glioblastoma.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34592195      PMCID: PMC8893120          DOI: 10.1016/S1470-2045(21)00488-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  83 in total

1.  Biomarker classifiers for identifying susceptible subpopulations for treatment decisions.

Authors:  Wei-Jiun Lin; James J Chen
Journal:  Pharmacogenomics       Date:  2011-12-21       Impact factor: 2.533

2.  A weighting analogue to pair matching in propensity score analysis.

Authors:  Liang Li; Tom Greene
Journal:  Int J Biostat       Date:  2013-07-31       Impact factor: 0.968

3.  Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.

Authors:  Stuart A Grossman; Karisa C Schreck; Karla Ballman; Brian Alexander
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

4.  Advantages of a Truly Open-Access Data-Sharing Model.

Authors:  Monica M Bertagnolli; Oliver Sartor; Bruce A Chabner; Mace L Rothenberg; Sean Khozin; Charles Hugh-Jones; David M Reese; Martin J Murphy
Journal:  N Engl J Med       Date:  2017-03-23       Impact factor: 91.245

Review 5.  Creating clinical trial designs that incorporate clinical outcome assessments.

Authors:  Mark R Gilbert; Lawrence Rubinstein; Glenn Lesser
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

6.  Prognostic factors for survival in adult patients with cerebral low-grade glioma.

Authors:  Francesco Pignatti; Martin van den Bent; Desmond Curran; Channa Debruyne; Richard Sylvester; Patrick Therasse; Denes Afra; Philippe Cornu; Michel Bolla; Charles Vecht; Abul B M F Karim
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

7.  Evaluating eligibility criteria of oncology trials using real-world data and AI.

Authors:  Ruishan Liu; Shemra Rizzo; Samuel Whipple; Navdeep Pal; Arturo Lopez Pineda; Michael Lu; Brandon Arnieri; Ying Lu; William Capra; Ryan Copping; James Zou
Journal:  Nature       Date:  2021-04-07       Impact factor: 69.504

8.  Single-arm Trials With External Comparators and Confounder Misclassification: How Adjustment Can Fail.

Authors:  Michael Webster-Clark; Michele Jonsson Funk; Til Stürmer
Journal:  Med Care       Date:  2020-12       Impact factor: 3.178

Review 9.  Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice.

Authors:  Ugonma N Chukwueke; Patrick Y Wen
Journal:  CNS Oncol       Date:  2019-02-26

Review 10.  Synthetic and External Controls in Clinical Trials - A Primer for Researchers.

Authors:  Kristian Thorlund; Louis Dron; Jay J H Park; Edward J Mills
Journal:  Clin Epidemiol       Date:  2020-05-08       Impact factor: 4.790

View more
  4 in total

Review 1.  Novel Clinical Trial Designs in Neuro-Oncology.

Authors:  Anurag Saraf; Lorenzo Trippa; Rifaquat Rahman
Journal:  Neurotherapeutics       Date:  2022-08-15       Impact factor: 6.088

Review 2.  Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe.

Authors:  Carla J Jonker; Elisabeth Bakker; Xavier Kurz; Kelly Plueschke
Journal:  Front Pharmacol       Date:  2022-08-04       Impact factor: 5.988

3.  Comprehensive analysis of m6A/m5C/m1A-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in glioma.

Authors:  Kai Zhao; Wenhu Li; Yongtao Yang; Xinyue Hu; Ying Dai; Minhao Huang; Ji Luo; Kui Zhang; Ninghui Zhao
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

4.  The design and evaluation of hybrid controlled trials that leverage external data and randomization.

Authors:  Brian M Alexander; Lorenzo Trippa; Steffen Ventz; Sean Khozin; Bill Louv; Jacob Sands; Patrick Y Wen; Rifaquat Rahman; Leah Comment
Journal:  Nat Commun       Date:  2022-10-02       Impact factor: 17.694

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.